On January 6–8, CFO Sara Bonstein executed three separate sales totaling 4,642 shares of INSM stock for aggregate proceeds of $808,733.06. Following these transactions, Bonstein’s stake fell by 5.56%, leaving her with 80,506 shares valued at approximately $14.0 million. These coordinated disposals were disclosed in multiple SEC filings and represent part of a broader insider sell-off over the same three-day window, in which CEO, COO and other executives collectively offloaded more than $15 million in company shares.

In the quarter ending September 30, INSM reported revenue of $142.34 million, beating analyst consensus of $114.33 million by 24.5% and marking a 52.4% year-over-year increase. Despite top-line strength, the company posted a loss per share of $1.75, missing estimates by $0.40 and widening from a loss of $1.27 in the prior-year period. Management reiterated full-year guidance for approximately $606.4 million in revenue, versus consensus near $520.7 million, driving shares higher but underscoring ongoing operating leverage pressures.

INSM updated key clinical milestones, pushing the ENCORE Phase 3 ARIKAYCE topline readout to March/April 2026 and the CEDAR Phase 2b brensocatib results to Q2 2026, concentrating near-term volatility around these catalysts. Meanwhile, Pomerantz LLP launched an investor investigation into the company, introducing potential litigation costs and reputational risk. Investors should monitor these timeline adjustments alongside pipeline spend projections for upcoming Phase 3 programs in PAH, PPF and IPF, which could further strain cash flow in the coming quarters.